Prometic Life Scienc (PFSCF) 2.3492 $PFSCF
ProMetic's plasminogen granted Fast Track designation by the US FDA
CNW Group - Mon Jun 13, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
reported today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to ProMetic for its plasminogen drug candidate, currently in a phase 2/3 clinical trial in patients suffering from congenital Plasminogen deficiency.
PLI.TO: 3.06 (+0.06)
ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting
CNW Group - Thu Jun 09, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" reported today that Dr. Lyne Gagnon, Vice-President of Preclinical R&D at ProMetic will be giving an oral presentation at the American Diabetic Association's upcoming annual meeting on PBI-4050's effect on keeping insulin-producing pancreatic beta cells alive.
PLI.TO: 3.06 (+0.06)
ProMetic announces closing of $60 million bought deal offering of common shares
CNW Group - Wed May 25, 8:54AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)("ProMetic" or the "Corporation" closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and which included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Limited (collectively, the "Underwriters" . ProMetic issued 19,400,000 common shares of the Corporation in connection with the Offering at a price of $3.10 per share for aggregate gross proceeds of $60,140,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission representing 5% of the gross proceeds of the Offering.
PLI.TO: 3.06 (+0.06)
Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis
CNW Group - Wed May 18, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported that it had been approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050, in patients suffering from cystic fibrosis ("CF" , following the CTA clearance by Health Canada. The objectives of this 24 week randomized, double-blind, and placebo-controlled Phase 2 study includes the evaluation of the effects of PBI-4050 on pancreatic and lung function in 90 CF patients.
PLI.TO: 3.06 (+0.06)
Global Emphysema Pipeline Report 2016 - Review of Abeona Therapeutics, Angion Biomedica, ProMetic Life Sciences & rEVO Biologics & Their Drug Profiles - Research and Markets
BusinessWire - Fri May 13, 5:08AM CDT
Research and Markets has announced the addition of the "Emphysema - Pipeline Review, H1 2016" report to their offering.
RBIO: (), ABEO: 2.37 (+0.05)
ProMetic Reports its First Quarter 2016 Highlights and Financial Results
CNW Group - Thu May 12, 3:59PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $5.2 million for the first quarter ended March 31, 2016 compared to $1.9 million for the first quarter ended March 31, 2015.
PLI.TO: 3.06 (+0.06)
Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Wed May 11, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that the plasminogen deficient patient treated under a compassionate use IND in the USA has shown an additional significant positive response to the treatment; in this case, in his kidney and urinary tract. The Corporation has previously reported the rapid healing of this patient's multiple 4 month old surgical wounds on his hand.
PLI.TO: 3.06 (+0.06)
Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Tue May 03, 5:45AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today the successful treatment of another plasminogen deficient patient, in the USA, under a compassionate use IND.
PLI.TO: 3.06 (+0.06)
ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells
CNW Group - Thu Apr 14, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" presented today new data at the 2016 European Association for the Study of the Liver (EASL)'s 51(st) Annual Meeting - The International Liver Congress (ILC) in Spain.
PLI.TO: 3.06 (+0.06)
ProMetic reports its 2015 fourth quarter and year end highlights and financial results
CNW Group - Wed Mar 30, 4:42PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $14.1 million and total revenues of $24.5 million for the fourth quarter and year ended December 31, 2015 respectively. This compares to revenues of $10.5 million and $23.0 million for the fourth quarter and year ended December 31, 2014 respectively.
PLI.TO: 3.06 (+0.06)
ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
PR Newswire - Tue Mar 22, 5:30AM CDT
-- Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
PLI.TO: 3.06 (+0.06)
ProMetic to report its fourth quarter and year end 2015 financial results and hold conference call / webcast
CNW Group - Mon Mar 21, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today announced that it will report its financial results for the fourth quarter and financial year ended December 31, 2015 on Wednesday March 30, 2016 after market close.
PLI.TO: 3.06 (+0.06)
ProMetic announces the addition of scleroderma to PBI-4050's targeted indications
CNW Group - Tue Mar 15, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma.
PLI.TO: 3.06 (+0.06)
Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share ownership pursuant to OSC Rule 62-504
CNW Group - Fri Mar 11, 5:36PM CST
Thomvest Asset Management Inc. ("Thomvest" today filed an initial report of its ownership of common shares and warrants of ProMetic Life Sciences Inc. (the "Corporation" pursuant to OSC Rule 62-504 and corresponding provisions of applicable securities laws in other Canadian jurisdictions.
Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.59 (unch), AZN: 30.11 (unch), GALT: 1.56 (+0.04)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.62 (+0.56), BCRX: 3.09 (+0.10), ISIS: 57.56 (-0.28), ARWR: 5.73 (+0.17), SHPG: 188.21 (-1.31), IBIO: 0.68 (unch), DYAX: 38.04 (-0.37)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.66 (+0.34), ISIS: 57.56 (-0.28), OPK: 9.87 (+0.01), ICPT: 151.73 (+7.98), XLRN: 34.75 (+0.84)
Global Wounds Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwsp8b/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wounds Overview - Therapeutics Development - Pipeline Products for Wounds - Overview - Pipeline Products for Wounds - Comparative Analysis - Wounds - Therapeutics under Development by Companies - Wounds - Therapeutics under Investigation by Universities/Institutes - Wounds - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wounds - Products under Development by Companies - Wounds - Products under Investigation by Universities/Institutes - Wounds - Companies Involved in Therapeutics Development - Advancell - Aerpio Therapeutics, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Berg LLC - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Molecular Design International, Inc. - NatureWise Biotech & Medicals Corporation - Novan, Inc. - Omeros Corporation - Pacific Northwest Biotechnology, LLC - ProMetic Life Sciences Inc. - Regenics AS - RXi Pharmaceuticals Corporation - Sanofi - Symic Biomedical, Inc. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/ww...s_pipeline
CRMD: 1.80 (-0.06), FGEN: 17.76 (+0.63), GSK: 43.38 (+0.04), CLBS: 0.57 (+0.03), OMER: 11.59 (-0.02)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.94 (+0.20), GALT: 1.56 (+0.04), ICPT: 151.73 (+7.98), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73), LPTN: 1.75 (-0.08)
ProMetic's plasminogen granted Fast Track designation by the US FDA
CNW Group - Mon Jun 13, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
reported today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to ProMetic for its plasminogen drug candidate, currently in a phase 2/3 clinical trial in patients suffering from congenital Plasminogen deficiency. PLI.TO: 3.06 (+0.06)
ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting
CNW Group - Thu Jun 09, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
reported today that Dr. Lyne Gagnon, Vice-President of Preclinical R&D at ProMetic will be giving an oral presentation at the American Diabetic Association's upcoming annual meeting on PBI-4050's effect on keeping insulin-producing pancreatic beta cells alive. PLI.TO: 3.06 (+0.06)
ProMetic announces closing of $60 million bought deal offering of common shares
CNW Group - Wed May 25, 8:54AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)("ProMetic" or the "Corporation"
closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and which included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Limited (collectively, the "Underwriters" . ProMetic issued 19,400,000 common shares of the Corporation in connection with the Offering at a price of $3.10 per share for aggregate gross proceeds of $60,140,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission representing 5% of the gross proceeds of the Offering. PLI.TO: 3.06 (+0.06)
Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis
CNW Group - Wed May 18, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported that it had been approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050, in patients suffering from cystic fibrosis ("CF" , following the CTA clearance by Health Canada. The objectives of this 24 week randomized, double-blind, and placebo-controlled Phase 2 study includes the evaluation of the effects of PBI-4050 on pancreatic and lung function in 90 CF patients. PLI.TO: 3.06 (+0.06)
Global Emphysema Pipeline Report 2016 - Review of Abeona Therapeutics, Angion Biomedica, ProMetic Life Sciences & rEVO Biologics & Their Drug Profiles - Research and Markets
BusinessWire - Fri May 13, 5:08AM CDT
Research and Markets has announced the addition of the "Emphysema - Pipeline Review, H1 2016" report to their offering.
RBIO: (), ABEO: 2.37 (+0.05)
ProMetic Reports its First Quarter 2016 Highlights and Financial Results
CNW Group - Thu May 12, 3:59PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $5.2 million for the first quarter ended March 31, 2016 compared to $1.9 million for the first quarter ended March 31, 2015. PLI.TO: 3.06 (+0.06)
Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Wed May 11, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that the plasminogen deficient patient treated under a compassionate use IND in the USA has shown an additional significant positive response to the treatment; in this case, in his kidney and urinary tract. The Corporation has previously reported the rapid healing of this patient's multiple 4 month old surgical wounds on his hand. PLI.TO: 3.06 (+0.06)
Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Tue May 03, 5:45AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today the successful treatment of another plasminogen deficient patient, in the USA, under a compassionate use IND. PLI.TO: 3.06 (+0.06)
ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells
CNW Group - Thu Apr 14, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
presented today new data at the 2016 European Association for the Study of the Liver (EASL)'s 51(st) Annual Meeting - The International Liver Congress (ILC) in Spain. PLI.TO: 3.06 (+0.06)
ProMetic reports its 2015 fourth quarter and year end highlights and financial results
CNW Group - Wed Mar 30, 4:42PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $14.1 million and total revenues of $24.5 million for the fourth quarter and year ended December 31, 2015 respectively. This compares to revenues of $10.5 million and $23.0 million for the fourth quarter and year ended December 31, 2014 respectively. PLI.TO: 3.06 (+0.06)
ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
PR Newswire - Tue Mar 22, 5:30AM CDT
-- Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
PLI.TO: 3.06 (+0.06)
ProMetic to report its fourth quarter and year end 2015 financial results and hold conference call / webcast
CNW Group - Mon Mar 21, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today announced that it will report its financial results for the fourth quarter and financial year ended December 31, 2015 on Wednesday March 30, 2016 after market close. PLI.TO: 3.06 (+0.06)
ProMetic announces the addition of scleroderma to PBI-4050's targeted indications
CNW Group - Tue Mar 15, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma. PLI.TO: 3.06 (+0.06)
Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share ownership pursuant to OSC Rule 62-504
CNW Group - Fri Mar 11, 5:36PM CST
Thomvest Asset Management Inc. ("Thomvest"
today filed an initial report of its ownership of common shares and warrants of ProMetic Life Sciences Inc. (the "Corporation" pursuant to OSC Rule 62-504 and corresponding provisions of applicable securities laws in other Canadian jurisdictions. Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.59 (unch), AZN: 30.11 (unch), GALT: 1.56 (+0.04)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.62 (+0.56), BCRX: 3.09 (+0.10), ISIS: 57.56 (-0.28), ARWR: 5.73 (+0.17), SHPG: 188.21 (-1.31), IBIO: 0.68 (unch), DYAX: 38.04 (-0.37)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.66 (+0.34), ISIS: 57.56 (-0.28), OPK: 9.87 (+0.01), ICPT: 151.73 (+7.98), XLRN: 34.75 (+0.84)
Global Wounds Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwsp8b/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wounds Overview - Therapeutics Development - Pipeline Products for Wounds - Overview - Pipeline Products for Wounds - Comparative Analysis - Wounds - Therapeutics under Development by Companies - Wounds - Therapeutics under Investigation by Universities/Institutes - Wounds - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wounds - Products under Development by Companies - Wounds - Products under Investigation by Universities/Institutes - Wounds - Companies Involved in Therapeutics Development - Advancell - Aerpio Therapeutics, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Berg LLC - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Molecular Design International, Inc. - NatureWise Biotech & Medicals Corporation - Novan, Inc. - Omeros Corporation - Pacific Northwest Biotechnology, LLC - ProMetic Life Sciences Inc. - Regenics AS - RXi Pharmaceuticals Corporation - Sanofi - Symic Biomedical, Inc. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/ww...s_pipeline
CRMD: 1.80 (-0.06), FGEN: 17.76 (+0.63), GSK: 43.38 (+0.04), CLBS: 0.57 (+0.03), OMER: 11.59 (-0.02)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.94 (+0.20), GALT: 1.56 (+0.04), ICPT: 151.73 (+7.98), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73), LPTN: 1.75 (-0.08)
